<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="20" offset="0" totalResults="61371"><SearchResults><Trial Id="99981"><Indications><Indication>Cardiovascular pregnancy complications</Indication></Indications><CompaniesSponsor><Company>Centre Hospitalier Universitaire de Nimes</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-02-01T00:00:00Z</DateChangeLast><DateEnd>2018-12-31T00:00:00Z</DateEnd><DateStart>2015-06-30T00:00:00Z</DateStart><Identifiers><Identifier>2014-A01120-47</Identifier><Identifier>LOCAL/2012/SB-01</Identifier><Identifier>NCT01736826</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Bloodwork alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>180</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The primary objective of this study is to demonstrate that plasma concentrations of nucleosomes and free DNA differ between three groups; pregnant patients with complications typical of placental insufficiency or venous thrombosis (group P), healthy women (Group T1) and healthy pregnant women (Group T2). The secondary objectives include the following: To describe, in 15 healthy, non-pregnant women changes in plasma concentrations of nucleosomes and free DNA over 3 months. To describe, in 15</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Thrombosis - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Laboratory/Diagnostic Measures - Assessment of blood chemistry</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Laboratory/Diagnostic Measures - Assessment of hematological parameters</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Platelet Count</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Free DNA and Nucleosome Concentrations in Pathological Pregnancies</TitleDisplay><PatientSegmentTerms><PatientSegment>Thrombosis - Subjects with Venous Thrombosis</PatientSegment><PatientSegment>Thrombosis - Subjects with Venous Thrombosis - Subjects with deep vein thrombosis</PatientSegment><PatientSegment>Thrombosis - Subjects with comorbid conditions - Subjects with vascular disorders</PatientSegment><PatientSegment>Thrombosis - Subjects with disease related complications - Subjects with pulmonary embolism</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Basophils </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Cell surface glycoprotein MUC18 </BiomarkerName><BiomarkerName> Cell-free DNA </BiomarkerName><BiomarkerName> D-dimer </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Granulocyte microparticles </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mean corpuscular volume </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Neutrophils</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>42 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Eve Mousty, MD</Name><Name>Sylvie Bouvier, MD</Name></ContactNames></Trial><Trial Id="99970"><Indications><Indication>Tooth injury</Indication></Indications><CompaniesCollaborator><Company>Septodont</Company></CompaniesCollaborator><CompaniesSponsor><Company>ASCOPHARM Groupe NOVASCO</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2017-10-17T00:00:00Z</DateChangeLast><DateEnd>2013-04-30T00:00:00Z</DateEnd><DateStart>2010-01-31T00:00:00Z</DateStart><Identifiers><Identifier>09/001</Identifier><Identifier>NCT01737229</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Biodentine (RD94) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>53</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this open-label, non-randomized study was to evaluate the efficacy and the tolerance of RD-94 in patients needing endodontic care, medical device class III.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and the Safety Study of RD-94 in Patients With Endodontic Care</TitleDisplay><PrimaryCompletionDate type="Actual">2013-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Chantal Naulin-Ifi, Docteur</Name><Name>Frédéric RILLIARD, Pr</Name><Name>Pierre Colon, Pr</Name></ContactNames></Trial><Trial Id="99969"><Indications><Indication>Prostate tumor</Indication></Indications><CompaniesSponsor><Company>Wheaton Franciscan Healthcare</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2014-10-31T00:00:00Z</DateEnd><DateStart>2011-08-31T00:00:00Z</DateStart><Identifiers><Identifier>11-019-ASH</Identifier><Identifier>NCT01408706</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Miller Enema Air Tip alone</Intervention><Intervention>Radiadyne Prostate Immobilizer Treatment Device alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to compare reproducibility of the device position and location of the prostate rectum interface between two immobilization devices for radiation therapy of prostate carcinoma.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>The Prostate Immobilization Device Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Prostate tumor - Subjects with Early Stage/Localized Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Locally Advanced Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage I Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage II Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage III Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with adenocarcinoma of prostate</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>38 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>James H Taylor, MD</Name></ContactNames></Trial><Trial Id="99965"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><CompaniesSponsor><Company>Japan Diabetes Foundation</Company><Company>Japan Diabetes Society</Company><Company>Japan Society for the Promotion of Science (JSPS)</Company><Company>Japanese Ministry of Health, Labor and Welfare</Company></CompaniesSponsor><DateChangeLast>2017-01-05T00:00:00Z</DateChangeLast><DateStart>2012-05-17T00:00:00Z</DateStart><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The purpose of this study was to examine the association between self-reported rate of eating and body mass index in Japanese patients with type 2 diabetes [ 1345636 ].</Teaser><TrialCategories><Category>Biomarker identification</Category></TrialCategories><TermsPatientSelection><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>A study to examine the association between self-reported rate of eating and body mass index in Japanese patients with type 2 diabetes-Japan diabetes clinical data management study group</TitleDisplay><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Sodium channel protein type 2 subunit alpha</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="99896"><Indications><Indication>Ocular hypertension</Indication><Indication>Open angle glaucoma</Indication></Indications><CompaniesSponsor><Company>Allergan Inc</Company></CompaniesSponsor><Countries><Country>Turkey</Country></Countries><DateChangeLast>2019-05-08T00:00:00Z</DateChangeLast><DateEnd>2014-04-10T00:00:00Z</DateEnd><DateStart>2013-03-07T00:00:00Z</DateStart><Identifiers><Identifier>MAF/AGN/OPH/GLA/037</Identifier><Identifier>NCT01735214</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>prostaglandin analog therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>358</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was a prospective, non-probability sample, observational study of changing from any intraocular pressure (IOP)-lowering treatment to a prostaglandin analog containing IOP-lowering medication for patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Glaucoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Glaucoma - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Glaucoma - Assessment of Therapy Related Outcomes - Assessment of treatment efficacy(unspecified)</EndpointIndex><EndpointIndex>Glaucoma - Assessment of ocular function - Assessment of intraocular pressure(IOP)</EndpointIndex><EndpointIndex>Ocular hypertension - Assessment of ocular function - Assessment of intraocular pressure(IOP)</EndpointIndex><EndpointIndex>Ocular hypertension - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Ocular hypertension - Patient Reported Outcomes/Quality of Life Assessments - Patient adherance</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments</TitleDisplay><PatientSegmentTerms><PatientSegment>Glaucoma - Subjects at risk of developing disease - Subjects with history of ocular hypertension(OHT)</PatientSegment><PatientSegment>Glaucoma - Subjects with History of/Scheduled for Therapy - Subjects with history/scheduled glaucoma medications</PatientSegment><PatientSegment>Glaucoma - Subjects with Primary Open-Angle Glaucoma(POAG)</PatientSegment><PatientSegment>Ocular hypertension - Subjects with Ocular Hypertension(OHT)</PatientSegment><PatientSegment>Ocular hypertension - Subjects with primary open-angle glaucoma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Intraocular pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-04-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Medical Director</Name></ContactNames></Trial><Trial Id="99879"><Indications><Indication>Lung disease</Indication></Indications><CompaniesSponsor><Company>Azienda Ospedaliera Universitaria San Martino</Company><Company>Istituto Nazionale per la Ricerca sul Cancro</Company></CompaniesSponsor><Countries><Country>Italy</Country></Countries><DateChangeLast>2018-07-20T00:00:00Z</DateChangeLast><DateEnd>2013-06-30T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>160197</Identifier><Identifier>33/2012</Identifier><Identifier>DLNO/DLCO</Identifier><Identifier>NCT01735526</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>allogeneic hematopoietic stem cells alone</Intervention><Intervention>autologous hematopoietic stem cell transplantation alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to study the changes in lung diffusing capacity for nitric oxide and carbon monoxide after allogeneic versus autologous hematopoietic stem-cell transplantation. The hypothesis for the changes that might occur after allogeneic hematopoietic stem-cell transplantation (allo-HSCT), (reductions of absolute lung volume and diffusing capacity for carbon monoxide [DLCO]) be due to an occult intersitial lung disease associated with infections, acute Graft-versus-Host Disease</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Therapy Related Outcomes - Assessment of efficacy/effectiveness of intervention</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>DLNO/DLCO: Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-Cell Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Allogenic Stem Cell Transplantation(SCT)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Hematopoietic Stem Cell Transplantation(HSCT)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Carbon monoxide diffusing capacity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Giovanni Barisione, MD</Name></ContactNames></Trial><Trial Id="99867"><Indications><Indication>Molybdenum cofactor deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Molybdenum cofactor synthesis protein stimulator</Action><Action>Unspecified enzyme modulator</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Enzyme technology</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Origin Biosciences Inc</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>US</Country><Country>Netherlands</Country><Country>UK</Country><Country>Turkey</Country><Country>Australia</Country></Countries><DateChangeLast>2019-03-20T00:00:00Z</DateChangeLast><DateEnd>2014-10-31T00:00:00Z</DateEnd><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>ALX-MCD-501</Identifier><Identifier>NCT01640717</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ALXN-1101 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of the study was to assess safety and efficacy data of Escherichia coli-derived cyclic pyranopterin monophosphate ( cPMP ) in patients with molybdenum cofactor deficiency (MoCD) [ 2043213 ]. By April 2013, the study was initiated [ 1410196 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Retrospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TitleDisplay>A Retrospective, Observational, Non-Interventional, Data Collection Study for Patients With Molybdenum Cofactor Deficiency Who Have Been Previously Treated With Cyclic Pyranopterin Monophosphate (cPMP)</TitleDisplay><PatientSegmentTerms><PatientSegment>Other metabolic disease - Subjects with comorbid conditions - Subjects co-morbid with Molybdenum cofactor deficiency</PatientSegment><PatientSegment>Other metabolic disease - Subjects with comorbid conditions - Subjects with isolated sulfite oxdiase deficiency</PatientSegment><PatientSegment>Other metabolic disease - Subjects with comorbid conditions - Subjects with suspected/diagnosed Molybdenum cofactor deficiency (MoCD) type A</PatientSegment><PatientSegment>Other metabolic disease - Subjects with comorbid conditions - Subjects with suspected/diagnosed Molybdenum cofactor deficiency (MoCD) type B</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>13</NumberOfSites></Trial><Trial Id="99839"><Indications><Indication>Metastatic non small cell lung cancer</Indication></Indications><CompaniesCollaborator><Company>Dana-Farber Cancer Institute Inc</Company><Company>MD Anderson Cancer Center</Company><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesCollaborator><CompaniesSponsor><Company>Massachusetts General Hospital</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-22T00:00:00Z</DateChangeLast><DateEnd>2016-09-30T00:00:00Z</DateEnd><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>12-353</Identifier><Identifier>NCT01734915</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Herringbone circulating tumor cell chip alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this research study was to determine if the EGFR mutation could be detected in CTCs (circulating tumor cell) using CTC-chip. Using this device, the investigators would test patients' blood to try and find CTCs with the EGFR mutation and compare them with the results from the biopsy. The long-term goal of this research was to develop a way to test for the EGFR mutation that is less invasive than a tumor biopsy.</Teaser><TrialCategories><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Oncogenes/Oncoproteins - Assessment of EGFR mutation/ amplification status</EndpointIndex><EndpointIndex>Lung tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Lung tumor - Protocol Specified Other Endpoints - Assessment of Treatment Feasibility</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Detecting EGFR T790M Mutations From Circulating Tumor Cells</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment><PatientSegment>Lung tumor - Subjects with Unresectable/In-operable Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with gene variants - EGFR_HUMAN_rs121434569(T)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cell-free DNA </BiomarkerName><BiomarkerName> Circulating Tumor Cells </BiomarkerName><BiomarkerName> Epidermal growth factor receptor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Greg Riely</Name><Name>John Heymach</Name><Name>Lecia Sequist</Name><Name>Pasi Janne</Name></ContactNames></Trial><Trial Id="99836"><Indications><Indication>Urolithiasis</Indication></Indications><CompaniesSponsor><Company>University of British Columbia</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2016-12-31T00:00:00Z</DateEnd><DateStart>2009-08-31T00:00:00Z</DateStart><Identifiers><Identifier>H08-02934</Identifier><Identifier>NCT01420354</Identifier></Identifiers><PatientCountEnrollment>21</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of this trial was to determine if limited urine collections would provide similar or more informative data than standard 24 h urine collections used to evaluate kidney stone formers. The investigators hypothesized that spot urines would provide equivalent information to that provided by a 24-h urine test. An added benefit would be if spot urines provide more information for the identification of risk factors in patients who have normal 24-h urine tests. A third possibility was that</Teaser><TrialCategories><Category>Diagnostic</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cross-sectional</Term></TermsDesign><EndpointIndex><EndpointIndex>Urolithiasis - Assessment of Minerals(Stone Composition) - Calcium levels</EndpointIndex><EndpointIndex>Urolithiasis - Assessment of Minerals(Stone Composition) - Citrate levels</EndpointIndex><EndpointIndex>Urolithiasis - Assessment of Minerals(Stone Composition) - Magnesium levels</EndpointIndex><EndpointIndex>Urolithiasis - Assessment of Minerals(Stone Composition) - Oxalate levels</EndpointIndex><EndpointIndex>Urolithiasis - Assessment of Underlying Systemic Conditions</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Can a Spot Urine Replace or Improve 24 h Urine Collections in Kidney Stone Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Urolithiasis - Subjects with Urolithiasis</PatientSegment><PatientSegment>Urolithiasis - Subjects with Urolithiasis - Subjects with calcium stones</PatientSegment><PatientSegment>Urolithiasis - Subjects with Urolithiasis - Subjects with renal stones</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Calcium </BiomarkerName><BiomarkerName> Citric Acid </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Magnesium </BiomarkerName><BiomarkerName> Oxalic acid</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>88 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dirk Lange</Name><Name>Meredith Cushing</Name><Name>Morris Pudek</Name><Name>Roger Sutton</Name><Name>Ryan Paterson</Name></ContactNames></Trial><Trial Id="99834"><Indications><Indication>Urolithiasis</Indication></Indications><CompaniesCollaborator><Company>University of Texas Southwestern Medical Center</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of British Columbia</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2021-12-31T00:00:00Z</DateEnd><DateStart>2012-12-31T00:00:00Z</DateStart><Identifiers><Identifier>H11-02525</Identifier><Identifier>NCT01735461</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>calcium carbonate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This primary objective of this study is to scientifically define an appropriate range of calcium supplementation that reduce the level of oxalate found in the urine of patients living with inflammatory bowel disease.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Crohns disease - Assessment of Laboratory/Diagnostic Measures - Assessment of urinary analysis</EndpointIndex><EndpointIndex>Crohns disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Urolithiasis - Assessment of Minerals(Stone Composition) - Calcium levels</EndpointIndex><EndpointIndex>Urolithiasis - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Calcium Supplements Strategy for Kidney Stones Prevention in Crohn's Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Crohns disease - Subjects with Extra-Intestinal Manifestations of Crohns Disease - Urological disorders</PatientSegment><PatientSegment>Crohns disease - Subjects with History of Surgical Intervention</PatientSegment><PatientSegment>Urolithiasis - Subjects with Urolithiasis - Subjects with renal stones</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Calcium oxalate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>108 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ben Chew, MD</Name><Name>Olga Arsovska</Name><Name>Ryan Paterson, MD</Name></ContactNames></Trial><Trial Id="99825"><Indications><Indication>Renal injury</Indication></Indications><CompaniesSponsor><Company>Cincinnati Children's Hospital Medical Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-23T00:00:00Z</DateChangeLast><DateEnd>2014-10-31T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>AKI-CHERUB</Identifier><Identifier>CIN001-AKI-CHERUB</Identifier><Identifier>NCT01735162</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>biomarkers analysis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>184</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In this AKI-CHERUB study, the investigators proposed to study renal angina in pediatric intensive care unit (PICU) patients alone and in combination with urinary biomarkers for acute kidney injury (AKI) prediction. The investigators hypothesized that renal angina would increase the predictive precision of urinary biomarkers for AKI.</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Renal failure - Assessment of Acute Renal Failure</EndpointIndex><EndpointIndex>Renal failure - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Replacement Therapy(RRT)</EndpointIndex><EndpointIndex>Renal failure - Protocol Specified Other Endpoints - Length of stay in hospital /ICU</EndpointIndex></EndpointIndex><TitleDisplay>AKI-CHERUB: Study of the Prediction of Acute Kidney Injury in Children Using Risk Stratification and Biomarkers</TitleDisplay><PatientSegmentTerms><PatientSegment>Renal failure - Hospitalized/ICU Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Hepatitis A virus cellular receptor 1 </BiomarkerName><BiomarkerName> Interleukin-18 </BiomarkerName><BiomarkerName> Neutrophil gelatinase-associated lipocalin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Stuart Goldstein, MD</Name></ContactNames></Trial><Trial Id="99783"><Indications><Indication>Myocardial infarction</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Erythropoietin ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hematopoietic stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Glycoprotein</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Japanese Ministry of Health, Labor and Welfare</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-05-11T00:00:00Z</DateChangeLast><DateEnd>2015-08-01T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>EPO-AMI-II</Identifier><Identifier>UMIN000005721</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>epoetin beta, Roche alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>600</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The purpose of this randomized, multicenter, placebo-controlled, double-blind, parallel study was to investigate whether the administration of epoetin beta (6000 or 12000 unit) to patients with ST-elevation acute myocardial infarction (STEMI) who underwent successful PCI within 12 h after onset was able to improve reperfusion injury in dose-dependent manner, and to estimate appropriate dose for clinical use [ 1345205 ], [ 1345243 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiac Function - Assessment by wall motion score index(WMSI)</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiac Function - Change in end-systolic and end-diastolic volumes</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiac Function - Changes in Left ventricular ejection fraction</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiac Markers</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events - Heart failure</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events - Non fatal myocardial infarction</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of MRI Imaging Findings - Evaluation of infarct size</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Reperfusion/Revascularization</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Survival</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Thrombotic/Thromboembolic Events - Ischemic stroke</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of hospitalization - Cause for hospitalization</EndpointIndex><EndpointIndex>Acute coronary syndrome - Hematological Assessments</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Function - Assessment by wall motion score index(WMSI)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Function - Assessment of Left ventricular function</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Function - Assessment of ejection fraction</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Area of infarction (percentage)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Fatal MI/Non-fatal MI</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Other Cardiovascular Events - Heart failure (New onset /Worsening)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Reperfusion/Revascularization</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Nonfatal cerebral infarction /Ischemic stroke</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of hospitalization</EndpointIndex><EndpointIndex>Coronary artery disease - Hematological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>EPO-AMI-II: EPO-AMI-II</TitleDisplay><PatientSegmentTerms><PatientSegment>Acute coronary syndrome - ST Segment Elevation Myocardial Infarction(STEMI) Subjects</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Abnormal Echo/ECG findings - Decreased ventricular ejection fraction</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Acute Myocardial Infarction (MI)</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with History of Cardiac Intervention</PatientSegment><PatientSegment>Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Complications of the Underlying IHD - Subjects with congestive heart failure</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Acute onset/new onset myocardial infarction (MI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Left ventricular ejection fraction </BiomarkerName><BiomarkerName> N-terminal Pro Brain Natriuretic Peptide</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>46 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Issei Komuro</Name><Name>Tetsuo Minamino</Name><Name>Yoshifusa Aizawa</Name></ContactNames></Trial><Trial Id="99778"><Indications><Indication>Autoimmune disease</Indication><Indication>Insulin dependent diabetes</Indication></Indications><CompaniesCollaborator><Company>National Institute for Health and Welfare, Finland</Company><Company>Tampere University Hospital</Company><Company>University of Turku</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Helsinki</Company></CompaniesSponsor><Countries><Country>Finland</Country></Countries><DateChangeLast>2017-09-14T00:00:00Z</DateChangeLast><DateEnd>2016-08-31T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>1DP3DK094338-01</Identifier><Identifier>EDIA</Identifier><Identifier>NCT01735123</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Cow's milk alone</Intervention><Intervention>Extensively hydrolyzed casein alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>87</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of the study was to identify the mechanism(s) by which an extensively hydrolyzed casein formula is able to protect children at risk for type 1 diabetes (T1D) from beta-cell autoimmunity.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Laboratory/Diagnostic Measures</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term></TermsPatientSelection><TitleDisplay>EDIA: Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity</TitleDisplay><PatientSegmentTerms><PatientSegment>Insulin dependent diabetes - Subjects at risk of developing disease</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects at risk of developing disease - Subjects with HLA genotypes that increase risk of type 1 diabetes mellitus</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Interleukin-17A </BiomarkerName><BiomarkerName> Intestinal permeability</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>43 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Mikael Knip, M.D.</Name></ContactNames></Trial><Trial Id="99771"><Indications><Indication>Inflammatory disease</Indication></Indications><CompaniesSponsor><Company>Lawson Health Research Institute</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2017-09-22T00:00:00Z</DateChangeLast><DateEnd>2011-09-30T00:00:00Z</DateEnd><DateStart>2005-09-30T00:00:00Z</DateStart><Identifiers><Identifier>11652E</Identifier><Identifier>NCT00229034</Identifier><Identifier>R-05-382</Identifier></Identifiers><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this observational study was to determine the effect of activated protein C (APC) and erythropoietin (Epo) in reducing the systemic inflammatory response during severe sepsis.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Sepsis - Assessment of Biomarkers</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effect of APC and Epo on the Inflammatory Response During Sepsis</TitleDisplay><PatientSegmentTerms><PatientSegment>Sepsis - Subjects with Sepsis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Erythropoietin </BiomarkerName><BiomarkerName> Vitamin K-dependent protein C</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>72 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Amit Badhwar, PhD</Name><Name>Neil Parry, MD</Name></ContactNames></Trial><Trial Id="9976"><Indications><Indication>HIV infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>DNA polymerase inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action><Action>RNA DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Film coating</Technology><Technology>Nucleotide and derivatives</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Achillion Pharmaceuticals Inc</Company></CompaniesSponsor><DateChangeLast>2017-04-03T00:00:00Z</DateChangeLast><DateStart>2003-04-27T00:00:00Z</DateStart><InterventionsControlDisplay><Intervention>lamivudine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>elvucitabine alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>A randomized study to evaluate the safety and efficacy of elvucitabine versus lamivudine in HIV-patients [ 489336 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A randomized study to evaluate the safety and efficacy of elvucitabine versus lamivudine in HIV-patients</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="99731"><ActionsPrimaryInterventionsPrimary><Action>Estradiol 17 beta dehydrogenase stimulator</Action><Action>Glucocorticoid receptor antagonist</Action><Action>PGE1 agonist</Action><Action>Progesterone receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antihyperlipidemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>Marie Stopes International</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2019-04-09T00:00:00Z</DateChangeLast><DateStart>2009-09-01T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12611001051932</Identifier></Identifiers><IndicationsAdverse><Indication>Bleeding</Indication><Indication>Pain</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including mifepristone , mifepristone + misoprostol , misoprostol</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>13345</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The aim of this observational, longitudinal, retrospective, Australian study was to assess the safety and efficacy of low-dose mifepristone followed by buccal misoprostol in early medical abortion [ 1344937 ], [ 1335997 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Longitudinal</Term><Term>Convenience Sample</Term><Term>Retrospective</Term></TermsDesign><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Female</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>An observational, longitudinal, retrospective, Australian study to assess the effect of low-dose mifepristone followed by buccal misoprostol in early medical abortion</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Business Development Director</Name></ContactNames></Trial><Trial Id="99715"><Indications><Indication>Hepatitis B virus infection</Indication><Indication>Hepatocellular carcinoma</Indication><Indication>Liver cirrhosis</Indication></Indications><CompaniesCollaborator><Company>National Natural Science Foundation of China</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sichuan University</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-03-24T00:00:00Z</DateChangeLast><DateEnd>2007-08-31T00:00:00Z</DateEnd><DateStart>2004-01-01T00:00:00Z</DateStart><Identifiers><Identifier>ChiCTR-OO-08000153</Identifier></Identifiers><PatientCountEnrollment>180</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of this open-label observational trial was to evaluate the effect and correlation of somatostatin, somatostatin receptors, cycloxygenase-2, HBV X protein and portal hypertension on the development of chronic hepatitis B, cirrhosis and hepatocellular carcinoma [ 1344927 ].</Teaser><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Effect of Somatostatin, Cycloxygenase-2, HBV X Protein and Portal Hypertension on the Development of Hepatocellular Carcinoma</TitleDisplay><BiomarkerNames><BiomarkerName>Somatostatin </BiomarkerName><BiomarkerName> Somatostatin receptors</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>44 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Tang Cheng-Wei</Name></ContactNames></Trial><Trial Id="99685"><Indications><Indication>Artery disease</Indication><Indication>Peripheral vascular disease</Indication></Indications><CompaniesCollaborator><Company>Boston Scientific Corp</Company></CompaniesCollaborator><CompaniesSponsor><Company>Provascular GmbH</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-12-08T00:00:00Z</DateChangeLast><DateEnd>2012-11-30T00:00:00Z</DateEnd><DateStart>2011-04-30T00:00:00Z</DateStart><Identifiers><Identifier>021-11-24012011</Identifier><Identifier>DRKS00003090</Identifier><Identifier>ISROTH10001</Identifier><Identifier>NCT01336101</Identifier><Identifier>Prov 01 - 2011</Identifier><Identifier>SUMMIT</Identifier><Identifier>U1111-1121-6816</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Epic Self-Expanding Nitinol Vascular Stent alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The intent of this clinical registry was to demonstrate the efficacy of the Epic stent in patients with superficial femoral/ popliteal artery disease (SFA). Study hypothesis: the Epic self-expanding nitinol vascular stent with delivery system would be efficacious in patients with superficial femoro/popliteal artery disease.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Imaging assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of procedural outcomes</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Angiographic Endpoints - Assessment of binary restenosis</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Success - Technical Success</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SUMMIT: Evaluation of Efficacy of the EPIC Self-Expanding Nitinol Vascular Stent</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Somatic Pain - Patients with claudication pain</PatientSegment><PatientSegment>Peripheral vascular disease - Subjects with Chronic Critical Limb Ischemia - Subjects with rest pain</PatientSegment><PatientSegment>Peripheral vascular disease - Subjects with Intermittent Claudication - Subjects with moderate claudication</PatientSegment><PatientSegment>Peripheral vascular disease - Subjects with Intermittent Claudication - Subjects with severe claudication</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arterial oxygen saturation </BiomarkerName><BiomarkerName> Blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>19 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Dierk Scheinert</Name><Name>Dominik Hornung</Name><Name>Janine Lieschke</Name><Name>Marcus Thieme</Name><Name>Thomas Nanning</Name><Name>Thomas Zeller</Name></ContactNames></Trial><Trial Id="99646"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><CompaniesSponsor><Company>Texas A&amp;M University System</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-04-12T00:00:00Z</DateChangeLast><DateEnd>2021-02-28T00:00:00Z</DateEnd><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2012-0561</Identifier><Identifier>NCT01734473</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>hydrolyzed casein protein alone</Intervention><Intervention>leucine alone</Intervention><Intervention>maltodextrin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>36</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This study will provide relevant clinical information in regards to the anabolic properties of specific dietary substrates and their co-active anabolic effects. Hypothesis: That supplementation of a hydrolyzed casein-based protein meal with the addition of carbohydrates is more anabolic than a hydrolyzed casein-based protein meal without carbohydrates in COPD patients and healthy older adults. That leucine addition to a hydrolyzed casein-based protein meal only enhances the protein anabolic</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance - Muscle force /strength</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Laboratory/Diagnostic Measures - Glucose evaluations</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Casein Protein and Leucine Supplementation in Chronic Obstructive Pulmonary Disease (COPD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body fat percentage </BiomarkerName><BiomarkerName> Bone mineral density </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Fat mass </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Interleukins </BiomarkerName><BiomarkerName> Maximal expiratory pressure </BiomarkerName><BiomarkerName> Maximal inspiratory mouth pressure </BiomarkerName><BiomarkerName> Muscle strength </BiomarkerName><BiomarkerName> Skeletal muscle mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>99 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Marielle PK Engelen, PhD</Name></ContactNames></Trial><Trial Id="9963"><Indications><Indication>Hepatitis B virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Nucleotide and derivatives</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Achillion Pharmaceuticals Inc</Company></CompaniesSponsor><DateChangeLast>2017-04-05T00:00:00Z</DateChangeLast><DateStart>2003-04-27T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>elvucitabine alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>In this study patients with hepatitis B viral infection were given elvucitabine in escalating doses to assess safety, efficacy, and pharmacokinetics [ 489336 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><TitleDisplay>Study to evaluate safety, efficacy and pharmacokinetics of elvucitabine in HBV-patients</TitleDisplay><BiomarkerNames><BiomarkerName>Hepatitis B virus DNA</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial></SearchResults></trialResultsOutput>